Estrogens and Endometrial Cancer in a Retirement Community

Overview

Journal N Engl J Med

Specialty General Medicine

Date 1976 Jun 3

PMID 177870

Citations 61

Authors

T M Mack

M C Pike

B E Henderson

R I Pfeffer

V R Gerkins

M Arthur

S E Brown

Affiliations

Soon will be listed here.

Abstract

All cases of endometrial cancer occurring among the residents of an affluent retirement community were compared with controls chosen from a roster of all women in the same community. Evidence of estrogen and other drug use and of selected medical conditions was obtained from three sources: medical records of the principal care facility, interviews, and the records of the local pharmacy. The risk ratio for any estrogen use was estimated from all available evidence to be 8.0 (95 per cent confidence interval, 3.5 to 18.1). and the for conjugated estrogen use to be 5.6 (95 per cent confidence interval, 2.8 to 11.1). Increased risk from estrogens was shown for invasive as well as noninvasive cancer, and a dose-response effect was demonstrated. For an estrogen user, the risk from endometrial cancer appeared to exceed by far the base-line risk from any other single cancer.

Citing Articles

Trend changes and factor analysis of endometrial hyperplasia in patients with polycystic ovarian syndrome based on the Korean National Health Insurance Database.

Park B, Lee H, Park S, Lee E, Lee J, Lee Y BMC Womens Health. 2022; 22(1):439.

PMID: 36348333 PMC: 9644593. DOI: 10.1186/s12905-022-02015-2.

Treating menopause - MHT and beyond.

Davis S, Baber R Nat Rev Endocrinol. 2022; 18(8):490-502.

PMID: 35624141 DOI: 10.1038/s41574-022-00685-4.

Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).

Lobo R, Liu J, Stanczyk F, Constantine G, Pickar J, Shadiack A Menopause. 2019; 26(7):720-727.

PMID: 30694918 PMC: 6636803. DOI: 10.1097/GME.0000000000001306.

Hypertension and the risk of endometrial cancer: a systematic review and meta-analysis of case-control and cohort studies.

Aune D, Sen A, Vatten L Sci Rep. 2017; 7:44808.

PMID: 28387226 PMC: 5384280. DOI: 10.1038/srep44808.

Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease.

Fu A, Sun S, Huang X, Amin A Int J Chron Obstruct Pulmon Dis. 2015; 10:909-15.

PMID: 25999706 PMC: 4435078. DOI: 10.2147/COPD.S83082.